IGHE and asthma: The anti-IgE monoclonal antibody omalizumab (Xolair) is widely used to reduce asthma exacerbations and the need for oral corticosteroids (OCSs) in severe allergic asthma (1–3), but there is no reliable way to predict its benefit.